+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Expression of the mid state differentiation b cell antigen gp 70 in patients with early and stable form of b chronic lymphocytic leukemia

Immunology Letters 12(5-6): 301-306
Expression of the mid state differentiation b cell antigen gp 70 in patients with early and stable form of b chronic lymphocytic leukemia
The expression of B-cell surface markers SmIg and GP-70 was determined on the mononuclear cells from the peripheral blood of 25 patients with chronic lymphocytic leukemia (CLL), 10 patients with multiple myeloma (MM), 6 normal blood donors and in 3 cases of unexplained persistent lymphocytosis. GP-70 was expressed only in CLL patients whereas multiple myloma patients, blood donors and patients with unexplained lymphocytosis were all negative to GP-70. SmIg was expressed in CLL patients and in some of the multiple myeloma patients. Subgrouping of CLL patients to "early", stable patients (10) and to more advanced CLL patients (15) revealed differential expression of GP-70 on CLL cells from patients with more advanced stage of disease rather than in the patients with the "early" stable clinical course of disease. SmIg, on the other hand, was expressed equally on both subgroups of CLL. Furthermore, in some cases (25%) where SmIg and the light chains of Ig were only weakly expressed or were absent, GP-70 was markedly expressed. These findings suggest that GP-70 can be used as a single laboratory determination to establish clonality of the B-lymphocyte proliferation in CLL. In addition, expression of GP-70 correlates with significant clinical parameters of the disease.

Accession: 005432120

Related references

Expression of the mid-stage differentiation B-cell antigen GP-70 in patients with early and stable form of B-CLL. Immunology Letters 12(5-6): 301-306, 1986

A new human T-cell differentiation antigen: unexpected expression on chronic lymphocytic leukemia cells. Immunogenetics 11(5): 429-439, 1980

Hairy cell leukemia hcl associated antigen b ly 7 is an activation differentiation associated antigen on hcl and normal b cells but not on b type chronic lymphocytic leukemia b cll cells. Leukemia & Lymphoma 6(2): 133-143, 1992

Increased T-cell reactivity to leukemic B cells in chronic lymphocytic leukemia with change of stable disease to its progressive form. American Journal of Hematology 10(2): 137-143, 1981

Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 9(7): 1227-1232, 1995

Surface antigen expression during induced proliferation and differentiation of b type chronic lymphocytic leukemia cells. Tissue Antigens 33(2): 165, 1989

B cell chronic lymphocytic leukemia with aberrant expression of cd8 antigen. European Journal of Haematology 39(4): 311-317, 1987

Association of CD38 antigen expression with other prognostic parameters in early stages of chronic lymphocytic leukemia. Leukemia & Lymphoma 42(6): 1315-1321, 2002

Recognition of antigen-specific B-cell receptors from chronic lymphocytic leukemia patients by synthetic antigen surrogates. Chemistry & Biology 21(12): 1670-1679, 2015

Expression of lymphocyte function-associated antigen (LFA)-1 in B-cell chronic lymphocytic leukemia. Leukemia & Lymphoma 13(5-6): 457-461, 1994